- Home
- SAVA vs NMP Comparison
SAVA vs NMP Comparison
Compare SAVA & NMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAVA | NMP |
|---|---|---|
| Founded | 1998 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.5M | 160.5M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | SAVA | NMP |
|---|---|---|
| Price | $1.98 | $10.03 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 15.8K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $9.90 |
| 52 Week High | $4.98 | $10.07 |
Technical Indicators
Market Signals| Indicator | SAVA | NMP |
|---|---|---|
| Relative Strength Index (RSI) | 30.54 | N/A |
| Support Level | $2.15 | N/A |
| Resistance Level | $3.32 | N/A |
| Average True Range (ATR) | 0.18 | 0.00 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 1.10 | 0.00 |
Price Performance
Historical ComparisonAbout SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About NMP NMP Acquisition Corp. Class A Ordinary Shares
NMP Acquisition Corp is a blank check company.